FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891788554> ?p ?o ?g. }

• W2891788554 endingPage "e620" @default.
• W2891788554 startingPage "e612" @default.
• W2891788554 abstract "Patients with epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) non-small-cell lung cancer commonly experience disease progression in the CNS. Here, we assess the impact of CNS disease on resource utilization and outcomes in patients who are EGFRm.We completed a retrospective review of all advanced patients who were EGFRm, referred to BC Cancer, and treated with a first- and/or second-generation EGFR tyrosine kinase inhibitor from 2010 to 2015. Baseline characteristics, systemic treatment, and CNS management were collected. We compared health resource utilization (HRU) between patients with CNS-negative disease and those with CNS metastases from the median time of CNS metastases diagnosis to death or last follow-up (9.1 months) and at 9 months preceding death or last follow-up for the CNS-negative group.Four hundred ninety-nine patients were referred, of which 68% were female; 51% were of Asian ethnicity; and 57%, 37%, and 6% were exon 19, 21, or other, respectively; with a median age of 66 years. Two hundred twenty-nine (46%) of 499 patients developed CNS metastases-39% at diagnosis and 61% over the course of disease. CNS metastases were managed with surgery with or without whole-brain radiotherapy (WBRT; 13%) WBRT alone (73%), stereotactic radiosurgery with or without WBRT (5%), or no CNS-directed therapy (9%). The median time from the development of CNS metastases diagnosis to death was 9.1 months. CNS-negative patients used less HRU versus patients that were CNS-positive in the 9 months preceding death or last follow-up-in the average number of clinic visits (8.53 v 12.71, respectively; P < .001), hospitalizations (0.43 v 0.76, respectively; P < .001), CNS imaging investigations (0.52 v 2.65, respectively; P < .001), emergency room visits (0.03 v 0.14, respectively; P = .001), palliative care unit admission (8% v 10%, respectively; P = .64), and hospice admission (3% v 19%, respectively; P < .001).The incidence of CNS metastases in patients with EGFRm is high and associated with increased HRU. Prevention or delay of CNS metastases with newer systemic therapy options may translate into lower resource utilization." @default.
• W2891788554 created "2018-09-27" @default.
• W2891788554 creator A5017402693 @default.
• W2891788554 creator A5025564062 @default.
• W2891788554 creator A5048614301 @default.
• W2891788554 creator A5051302388 @default.
• W2891788554 date "2018-10-01" @default.
• W2891788554 modified "2023-10-13" @default.
• W2891788554 title "CNS Metastases in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: Impact on Health Resource Utilization" @default.
• W2891788554 cites W1550632220 @default.
• W2891788554 cites W1974820090 @default.
• W2891788554 cites W1985325634 @default.
• W2891788554 cites W1995038009 @default.
• W2891788554 cites W2016112560 @default.
• W2891788554 cites W2018969856 @default.
• W2891788554 cites W2037139573 @default.
• W2891788554 cites W2040561412 @default.
• W2891788554 cites W2041835001 @default.
• W2891788554 cites W2047427936 @default.
• W2891788554 cites W2047930883 @default.
• W2891788554 cites W2093614047 @default.
• W2891788554 cites W2096198395 @default.
• W2891788554 cites W2099530756 @default.
• W2891788554 cites W2099725888 @default.
• W2891788554 cites W2104165122 @default.
• W2891788554 cites W2111662961 @default.
• W2891788554 cites W2127199535 @default.
• W2891788554 cites W2143843774 @default.
• W2891788554 cites W2147016542 @default.
• W2891788554 cites W2153235726 @default.
• W2891788554 cites W2155073814 @default.
• W2891788554 cites W2162887147 @default.
• W2891788554 cites W2165694430 @default.
• W2891788554 cites W2166084034 @default.
• W2891788554 cites W2168856723 @default.
• W2891788554 cites W2171139285 @default.
• W2891788554 cites W2222864127 @default.
• W2891788554 cites W2290578604 @default.
• W2891788554 cites W2300932108 @default.
• W2891788554 cites W2325642881 @default.
• W2891788554 cites W2329793926 @default.
• W2891788554 cites W2397460919 @default.
• W2891788554 cites W2416791964 @default.
• W2891788554 cites W2492450141 @default.
• W2891788554 cites W2494292000 @default.
• W2891788554 cites W2521664370 @default.
• W2891788554 cites W2528962190 @default.
• W2891788554 cites W2555516405 @default.
• W2891788554 cites W2560717039 @default.
• W2891788554 cites W2581511343 @default.
• W2891788554 cites W2581996620 @default.
• W2891788554 cites W2600540592 @default.
• W2891788554 cites W2601045707 @default.
• W2891788554 cites W2610816290 @default.
• W2891788554 cites W2624310346 @default.
• W2891788554 cites W2666096222 @default.
• W2891788554 cites W2738531764 @default.
• W2891788554 cites W2740569386 @default.
• W2891788554 cites W2761139746 @default.
• W2891788554 cites W2767072667 @default.
• W2891788554 cites W2767552869 @default.
• W2891788554 cites W2769765347 @default.
• W2891788554 cites W2770828094 @default.
• W2891788554 cites W2776194348 @default.
• W2891788554 cites W2784623697 @default.
• W2891788554 cites W2794627893 @default.
• W2891788554 doi "https://doi.org/10.1200/jop.18.00054" @default.
• W2891788554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30216125" @default.
• W2891788554 hasPublicationYear "2018" @default.
• W2891788554 type Work @default.
• W2891788554 sameAs 2891788554 @default.
• W2891788554 citedByCount "6" @default.
• W2891788554 countsByYear W28917885542019 @default.
• W2891788554 countsByYear W28917885542020 @default.
• W2891788554 countsByYear W28917885542023 @default.
• W2891788554 crossrefType "journal-article" @default.
• W2891788554 hasAuthorship W2891788554A5017402693 @default.
• W2891788554 hasAuthorship W2891788554A5025564062 @default.
• W2891788554 hasAuthorship W2891788554A5048614301 @default.
• W2891788554 hasAuthorship W2891788554A5051302388 @default.
• W2891788554 hasBestOaLocation W28917885541 @default.
• W2891788554 hasConcept C121608353 @default.
• W2891788554 hasConcept C126322002 @default.
• W2891788554 hasConcept C143998085 @default.
• W2891788554 hasConcept C167135981 @default.
• W2891788554 hasConcept C2776256026 @default.
• W2891788554 hasConcept C2777714996 @default.
• W2891788554 hasConcept C2779134260 @default.
• W2891788554 hasConcept C2779438470 @default.
• W2891788554 hasConcept C2780387249 @default.
• W2891788554 hasConcept C509974204 @default.
• W2891788554 hasConcept C71924100 @default.
• W2891788554 hasConceptScore W2891788554C121608353 @default.
• W2891788554 hasConceptScore W2891788554C126322002 @default.
• W2891788554 hasConceptScore W2891788554C143998085 @default.
• W2891788554 hasConceptScore W2891788554C167135981 @default.
• W2891788554 hasConceptScore W2891788554C2776256026 @default.
• W2891788554 hasConceptScore W2891788554C2777714996 @default.

• next